JAK Inhibitors Don't Disrupt Menstrual Health in Women with Rheumatoid Arthritis

For women with rheumatoid arthritis during their reproductive years, choosing the right treatment involves balancing disease control with potential effects on fertility and menstrual health. This concern is particularly relevant for JAK inhibitors, newer medications that block the JAK-STAT pathway involved in both immune responses and ovarian function.

Researchers studied 100 reproductive-aged women with rheumatoid arthritis receiving stable treatment for at least three months. They compared menstrual outcomes among those taking JAK inhibitors, TNF inhibitors, other biologics, or methotrexate using structured questionnaires about pre-treatment and during-treatment menstrual patterns.

The results were reassuring: while menstrual disturbances occurred across all treatment groups, JAK inhibitors didn't cause more problems than established therapies. Overall, 41% experienced altered cycle frequency, 18% had irregular bleeding, 10% developed absent periods, and 10% had heavy bleeding. Importantly, when researchers adjusted for factors like BMI and disease activity, JAK inhibitors showed no increased risk of amenorrhea compared to other treatments.

These findings matter for longevity and health optimization because untreated rheumatoid arthritis accelerates aging through chronic inflammation, increasing cardiovascular disease risk and reducing lifespan. Women can now consider JAK inhibitors without additional reproductive health concerns, potentially achieving better disease control and long-term health outcomes. However, this was a relatively small, retrospective study from a single center, and larger prospective studies would strengthen these conclusions.